Roles of SCC-Ag,CA19-9 and VEGF for chemotherapy efficacy in advanced esophageal squamous cell carcinoma

doi:10.3969/j.issn.1673-8640.2021.01.004

Abstract

Abstract:

Objective To investigate the roles of squamous cell carcinoma antigen（SCC-Ag）,carbohydrate antigen 19-9（CA19-9） and vascular endothelial growth factor（VEGF） for chemotherapy efficacy in advanced esophageal squamous cell carcinoma. Methods Totally,112 patients with advanced esophageal squamous cell carcinoma were enrolled. All the patients were treated with docetaxel + nedaplatin. Serum levels of SCC-Ag,CA19-9 and VEGF before and after chemotherapy were determined by enzyme-linked immunosorbent assay,and the chemotherapy efficacy of SCC-Ag,CA19-9 and VEGF was evaluated by receiver operating characteristic（ROC） curve. Results The effective rate of chemotherapy in 112 patients with esophageal squamous cell carcinoma was 53.57%（60/112）. There was no statistical significance in serum levels of SCC-Ag,CA19-9 and VEGF between effective chemotherapy group and ineffective chemotherapy group（P>0.05）. Serum levels of SCC-Ag,CA19-9 and VEGF in effective chemotherapy group after chemotherapy were lower than those before chemotherapy（P<0.001）,and serum levels of SCC-Ag,CA19-9 and VEGF in ineffective chemotherapy group after chemotherapy were higher than those before chemotherapy（P<0.001）. The suppression ratios of SCC-Ag,CA19-9 and VEGF in effective chemotherapy group were higher than those in ineffective chemotherapy group（P<0.001）. ROC curve analysis results showed that the area under curve（AUC） of the suppression ratios of SCC-Ag,CA19-9 and VEGF in evaluating the chemotherapy efficacy of esophageal squamous cell carcinoma were 0.741,0.712 and 0.783,the optimal cut-off values were 20%,26% and 27%,the sensitivities were 76.67%,80.00% and 83.33%,the specificities were 76.92%,73.08% and 80.77%,respectively. The AUC of the combination of the 3 factors（SCC-Ag suppression ratio >20%,CA19-9 suppression ratio >26%,VEGF suppression ratio >27%） in evaluating the chemotherapy efficacy of esophageal squamous cell carcinoma was 0.926,the sensitivity was 96.67%,and the specificity was 96.15%. Conclusions SCC-Ag,CA19-9 and VEGF can be used to evaluate the chemotherapy efficacy of advanced esophageal squamous cell carcinoma.

Key words: Squamous cell carcinoma antigen, Carbohydrate antigen 19-9, Vascular endothelial growth factor, Esophageal squamous cell carcinoma, Chemotherapy, Efficacy evaluation

CLC Number:

R446.1

YANG Yong. Roles of SCC-Ag,CA19-9 and VEGF for chemotherapy efficacy in advanced esophageal squamous cell carcinoma[J]. Laboratory Medicine, 2021, 36(1): 20-24.

Figures/Tables 3

References 12

[1]	吴瑾,周莉华,齐立伟. 多西他赛与奈达铂联合放疗对老年食管癌患者血清指标及肿瘤循环细胞的影响[J]. 中国老年学杂志,2018,38(24):5949-5952.
[2]	LIN J B,HUNG L C,CHENG C Y,et al.Prognostic significance of lung radiation dose in patients with esophageal cancer treated with neoadjuvant chemoradiotherapy[J]. Radiat Oncol,2019,14(1):85.
[3]	陈瑜,杨龙. 热疗对食管癌患者的辅助治疗作用及其对血清糖类抗原199及血管内皮生长因子的影响[J]. 中华老年多器官疾病杂志,2018,17(9):677-681.
[4]	程海花,许利华. 奈达铂联合多西他赛并同期放疗治疗不可手术食管癌的疗效[J]. 中国临床药学杂志,2019,28(3):176-179.
[5]	KAWAGOE S,NAKANO M,UCHINO K,et al.Analysis of response evaluation criteria in solid tumors reduction ratio of primary chemotherapy in unresectable advanced or recurrent colorectal cancer[J]. Mol Clin Oncol,2019,11(3):243-251.
[6]	许刚,王燕,王承伟,等. 食管癌放化疗中循环肿瘤细胞的变化及其临床意义[J]. 中国肿瘤临床,2016,43(9):381-384.
[7]	CHEN Y,CHENG X,SONG H,et al.Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for esophageal squamous cell cancer patients presenting with oligometastases[J]. J Thorac Dis,2019,11(4):1536-1545.
[8]	JING S W,QIN J J,LIU Q,et al.Comparison of neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for esophageal cancer:a meta-analysis[J]. Future Oncol,2019,15(20):2413-2422.
[9]	朱焕锋,解鹏,王洁,等. 食管癌患者血清血管内皮生长因子和基质金属蛋白酶9的表达及其临床意义[J]. 肿瘤研究与临床,2017,29(3):160-163.
[10]	QIAO Y,CHEN C,YUE J,et al.Tumor marker index based on preoperative SCC and CYFRA 21-1 is a significant prognostic factor for patients with resectable esophageal squamous cell carcinoma[J]. Cancer Biomark,2019,25(3):243-250.
[11]	VAN DER KAAIJ R T,VONCKEN F E M,VAN DIEREN J M,et al. Elevated pretreatment CEA and CA19-9 levels are related to early treatment failure in esophageal adenocarcinoma[J]. Am J Clin Oncol,2019,42(4):345-350.
[12]	孙威,孙志强,汪建林,等. 食管癌放疗肿瘤病理缓解程度及血管内皮生长因子变化与预后的相关性分析[J]. 中华放射医学与防护杂志,2018,38(7):517-523.

组别	例数	SCC-Ag
组别	例数	化疗前/（µg/L）	化疗后/（µg/L）	t值	P值	下降比/%
化疗无效组	52	5.06±0.57	6.21±0.84	8.775	<0.001	-24.55±3.04
化疗有效组	60	4.94±0.53	3.22±0.47	17.509	<0.001	34.34±4.91
t值		1.148	22.757			77.381
P值		0.254	<0.001			<0.001
组别		CA19-9
组别		化疗前/（U/mL）	化疗后/（U/mL）	t值	P值	下降比/%
化疗无效组		85.75±9.88	101.64±12.12	7.871	<0.001	-19.05±2.86
化疗有效组		84.21±9.82	54.75±7.02	17.599	<0.001	35.43±4.05
t值		0.825	24.548			83.035
P值		0.411	<0.001			<0.001
组别		VEGF
组别		化疗前/（ng/L）	化疗后/（ng/L）	t值	P值	下降比/%
化疗无效组		270.52±30.82	331.29±35.61	9.995	<0.001	-22.59±3.08
化疗有效组		268.23±30.13	163.52±24.06	19.583	<0.001	39.25±5.19
t值		0.396	28.751			77.852
P值		0.693	<0.001			<0.001

组别	例数	SCC-Ag
组别	例数	化疗前/（µg/L）	化疗后/（µg/L）	t值	P值	下降比/%
化疗无效组	52	5.06±0.57	6.21±0.84	8.775	<0.001	-24.55±3.04
化疗有效组	60	4.94±0.53	3.22±0.47	17.509	<0.001	34.34±4.91
t值		1.148	22.757			77.381
P值		0.254	<0.001			<0.001
组别		CA19-9
组别		化疗前/（U/mL）	化疗后/（U/mL）	t值	P值	下降比/%
化疗无效组		85.75±9.88	101.64±12.12	7.871	<0.001	-19.05±2.86
化疗有效组		84.21±9.82	54.75±7.02	17.599	<0.001	35.43±4.05
t值		0.825	24.548			83.035
P值		0.411	<0.001			<0.001
组别		VEGF
组别		化疗前/（ng/L）	化疗后/（ng/L）	t值	P值	下降比/%
化疗无效组		270.52±30.82	331.29±35.61	9.995	<0.001	-22.59±3.08
化疗有效组		268.23±30.13	163.52±24.06	19.583	<0.001	39.25±5.19
t值		0.396	28.751			77.852
P值		0.693	<0.001			<0.001

[1]	JIANG Mengying, LIU Yiwen, HE Yiqing, XU Jing, YANG Cuixia, GAO Feng, DU Yan. Clinical role of serum S1P in the early diagnosis of colorectal cancer [J]. Laboratory Medicine, 2023, 38(4): 307-312.
[2]	YUAN Shuang, FENG Lei, GUO Xiaofen, FU Xiaoling, XU Jing, LIU Hongyang. Relation of miR-433 in endometrial cancer tissues and its relationship with chemotherapy sensitivity [J]. Laboratory Medicine, 2023, 38(4): 337-341.
[3]	CHEN Zhe, ZHANG Ling, LIU Jie, WANG Xia, ZHANG Bin, GAO Binghua. Relationship between serum miR-326 and chemotherapy sensitivity and prognosis in patients with treatment-related hematological malignancy [J]. Laboratory Medicine, 2023, 38(3): 251-256.
[4]	GAO Jianchao, WANG Sisi, ZHANG Zhisheng, ZHANG Jingli, LI Xiaoxia, MA Ke, FENG Zhilin, ZHOU Haifeng, WANG Zhanhai. Efficacy and prognosis evaluation of neo-adjuvant chemotherapy for breast cancer based on miR-206，miR-125 and miR-21 [J]. Laboratory Medicine, 2023, 38(11): 1062-1068.
[5]	ZHANG Meng, LI Sha, CHANG Yanli, WANG Lu, XU Jianjun, ZHANG Qingyun. Role of vascular endothelial growth factor in monitoring treatment outcome and evaluating the prognosis of patients with advanced melanoma [J]. Laboratory Medicine, 2022, 37(9): 821-825.
[6]	WEN Jing, SHI Rui, XIE Jia, LIU Feng, LI Guang, REN Jingjing, LEI Xiaoru, GUO Xiaobo, SONG Yanping. Clinical application of metagenomic next-generation sequencing for determining pathogens in febrile neutropenic patients [J]. Laboratory Medicine, 2022, 37(9): 855-859.
[7]	LIANG Chunfang, ZHU Kangning, ZHANG Qi. Serum miR-21 and miR-135a expression levels in predicting the recurrence and metastasis of gastric cancer patients after chemotherapy [J]. Laboratory Medicine, 2022, 37(5): 417-422.
[8]	GAO Feng. Research progress of new tumor molecular markers in the age of precision medicine：from accurate diagnosis to precision chemotherapy [J]. Laboratory Medicine, 2022, 37(4): 309-312.
[9]	GONG Zhiyun, JIANG Minglei, SHI Weizhong, LU Renquan, GUO Lin. Application value of fecal SDC2 gene methylation determination in the auxiliary diagnosis of colorectal cancer [J]. Laboratory Medicine, 2022, 37(4): 325-329.
[10]	WANG Jianying, WANG Shanshan, ZHU Jun, HUANG Xiaochun, WAN Yuxiang, LIU Yun. Distribution and drug resistance of respiratory infection pathogens in patients with lung cancer after chemotherapy [J]. Laboratory Medicine, 2022, 37(4): 356-359.
[11]	MAN Xianfeng, HE Xiaoting, ZHANG Ying, YU Weiwei, WANG Qi, YIN Hanwei, WANG Runjie. Application of thioredoxin reductase in monitoring the curative effect of lung cancer [J]. Laboratory Medicine, 2022, 37(1): 56-59.
[12]	HU Tao, LU Renquan, GUO Lin. Auxiliary diagnostic and clinical prognostic evaluation value of thymidine kinase 1 determination in hepatocellular cancer [J]. Laboratory Medicine, 2021, 36(9): 914-919.
[13]	LIN Jiafei, CHEN Xiaosong, WU Beiying, CAI Gang, LIN Lin. 21-Gene recurrence score in mucinous breast cancer [J]. Laboratory Medicine, 2021, 36(7): 714-718.
[14]	LI Bin, ZHAO Dong, HUANG Rong, GUO Juansun. Role of bone marrow vascular endothelial growth factor levels in patients with diffuse large B-cell lymphoma after treatment [J]. Laboratory Medicine, 2021, 36(5): 480-485.
[15]	LI Huiping, ZHENG Dayong, YANG Shuai, ZHOU Yunli. Role of serum pro-gastrin releasing peptide in patients with small cell lung cancer [J]. Laboratory Medicine, 2020, 35(4): 310-313.